Apellis Pharmaceuticals, Inc. (APLS) financial statements (2022 and earlier)

Company profile

Business Address 100 FIFTH AVENUE
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments701878352176176
Cash and cash equivalents640566352176176
Short-term investments60312   
Restricted cash and investments21   
Receivables10    
Inventory, net of allowances, customer advances and progress billings16    
Inventory16    
Prepaid expense251120245
Other current assets7127100
Other undisclosed current assets   11
Total current assets:824917373202182
Noncurrent Assets
Operating lease, right-of-use asset201814
Property, plant and equipment672  
Other noncurrent assets3219010
Total noncurrent assets:58431610
TOTAL ASSETS:882961389204182
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12012063157
Accounts payable1788104
Accrued liabilities1031125553
Debt  32 
Other undisclosed current liabilities128   
Total current liabilities:13212866177
Noncurrent Liabilities
Long-term debt and lease obligation2063741541920
Long-term debt, excluding current maturities1893591431920
Operating lease, liability171512
Liabilities, other than long-term debt   77
Due to related parties   77
Other undisclosed noncurrent liabilities32823813500
Total noncurrent liabilities:5516282892627
Total liabilities:6837563554333
Stockholders' equity
Stockholders' equity attributable to parent19920534161149
Common stock00000
Additional paid in capital1,8571,131616438298
Accumulated other comprehensive loss(2)(0)(0)(0) 
Accumulated deficit(1,657)(926)(581)(277)(149)
Total stockholders' equity:19920534161149
TOTAL LIABILITIES AND EQUITY:882961389204182

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues67251   
Gross profit:67251   
Operating expenses(603)(464)(288)(128)(51)
Operating loss:(536)(214)(288)(128)(51)
Nonoperating income24530
Investment income, nonoperating0453 
Other nonoperating income (expense)1(1)(0)(0)0
Interest and debt expense  (2)  
Other undisclosed loss from continuing operations before equity method investments, income taxes (133)(20)  
Loss from continuing operations before equity method investments, income taxes:(534)(343)(305)(125)(51)
Other undisclosed loss from continuing operations before income taxes(212)    
Loss from continuing operations before income taxes:(746)(343)(305)(125)(51)
Income tax expense(0)(2)   
Loss before gain (loss) on sale of properties:(746)(345)(305)(125)(51)
Other undisclosed net loss   (2) 
Net loss:(746)(345)(305)(128)(51)
Other undisclosed net loss attributable to parent    (0)
Net loss available to common stockholders, diluted:(746)(345)(305)(128)(51)

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(746)(345)(305)(128)(51)
Other comprehensive income 0   
Comprehensive loss:(746)(345)(305)(128)(51)
Other undisclosed comprehensive loss, net of tax, attributable to parent(2) (0)(0) 
Comprehensive loss, net of tax, attributable to parent:(748)(345)(305)(128)(51)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: